Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $106.62 million. The enterprise value is -$128.26 million.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 82.98 million shares outstanding. The number of shares has increased by 8.39% in one year.
| Current Share Class | 82.98M |
| Shares Outstanding | 82.98M |
| Shares Change (YoY) | +8.39% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 62.73% |
| Float | 82.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.24 |
| Forward PS | 19.10 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.26.
| Current Ratio | 3.75 |
| Quick Ratio | 3.71 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.10% and return on invested capital (ROIC) is -53.82%.
| Return on Equity (ROE) | -98.10% |
| Return on Assets (ROA) | -35.52% |
| Return on Invested Capital (ROIC) | -53.82% |
| Return on Capital Employed (ROCE) | -90.38% |
| Revenue Per Employee | $131,358 |
| Profits Per Employee | -$963,793 |
| Employee Count | 246 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.03% in the last 52 weeks. The beta is 2.16, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.16 |
| 52-Week Price Change | -78.03% |
| 50-Day Moving Average | 1.47 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 49.43 |
| Average Volume (20 Days) | 2,111,544 |
Short Selling Information
The latest short interest is 12.68 million, so 15.29% of the outstanding shares have been sold short.
| Short Interest | 12.68M |
| Short Previous Month | 13.15M |
| Short % of Shares Out | 15.29% |
| Short % of Float | 15.34% |
| Short Ratio (days to cover) | 5.06 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $32.31 million and -$237.09 million in losses. Loss per share was -$2.88.
| Revenue | 32.31M |
| Gross Profit | -166.93M |
| Operating Income | -238.92M |
| Pretax Income | -193.45M |
| Net Income | -237.09M |
| EBITDA | -233.11M |
| EBIT | -238.92M |
| Loss Per Share | -$2.88 |
Full Income StatementBalance Sheet
The company has $269.91 million in cash and $35.03 million in debt, giving a net cash position of $234.88 million or $2.83 per share.
| Cash & Cash Equivalents | 269.91M |
| Total Debt | 35.03M |
| Net Cash | 234.88M |
| Net Cash Per Share | $2.83 |
| Equity (Book Value) | 134.27M |
| Book Value Per Share | 1.62 |
| Working Capital | 212.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$210.28 million and capital expenditures -$8.83 million, giving a free cash flow of -$219.11 million.
| Operating Cash Flow | -210.28M |
| Capital Expenditures | -8.83M |
| Free Cash Flow | -219.11M |
| FCF Per Share | -$2.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -739.37% |
| Pretax Margin | -733.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.39% |
| Shareholder Yield | -8.39% |
| Earnings Yield | -222.36% |
| FCF Yield | -205.50% |
Analyst Forecast
The average price target for Editas Medicine is $8.08, which is 528.79% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.08 |
| Price Target Difference | 528.79% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | -10.02% |
| EPS Growth Forecast (5Y) | -13.97% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -6.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.26 |
| Piotroski F-Score | 1 |